(Toronto and London, UK) – The Centre for Commercialization of Regenerative Medicine (CCRM) and the Cell Therapy Catapult, government-funded translation centres in Canada and the UK respectively, have signed a collaboration agreement solidifying their intent to work together. The partners will work to support the development and commercialization of cell therapy and regenerative medicine opportunities from the high- impact technological discoveries emerging in their respective countries.
Under the terms of their agreement, the CCRM and the Cell Therapy Catapult plan to work together on suitable R&D projects, clinical trials, standardization and regulatory efforts, as well as initiatives such as training. The governments in Canada and the UK have identified the field of cell therapy and regenerative medicine for its potential ability to increase each nation’s health and wealth. CCRM and the Cell Therapy Catapult are centres of excellence that are well aligned to deliver on this potential.
“CCRM and the Cell Therapy Catapult are both committed to moving potential therapeutic approaches from early stage research to the marketplace and there are many good arguments for combining our strengths and resources, and doing this together,” explains Dr. Michael May, CEO of CCRM. “If we can commercialize research faster and more effectively by partnering, then everyone benefits – especially the patient.”
“CCRM and the Cell Therapy Catapult are both committed to moving potential therapeutic approaches from early stage research to the marketplace and there are many good arguments for combining our strengths and resources, and doing this together.
Dr. Michael May, CEO of CCRM
Keith Thompson, CEO of the Cell Therapy Catapult, said “We are delighted to have formed this important international link with CCRM, which provides us with access to a strong network of academics, companies and entrepreneurs in Canada. The anticipated exchange of ideas and technological expertise, as well as collaborative activity, will be of great benefit to patients and the cell therapy industries in both countries.”